{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"25.0","value":"9.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive:\n\nPembrolizumab 200 mg IV on Day 1 of each 21-day cycle (±3 days) for Cycles 1 and 2 in participants enrolled in Part II (lead-in therapy).\n\n9-ING-41 twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit.\n\nCarboplatin once per 21-day cycle on Day 1 for up to 1 year.","id":"OG000","title":"Evaluable Patients Popupulation"}],"paramType":"NUMBER","populationDescription":"According to the protocol, all evaluable patients were combined for the primary analysis.","reportingStatus":"POSTED","timeFrame":"Tumor assessments were performed every 3 cycles (each cycle was 21 days), for up to 15.6 months.","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}